Our Approach
Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (acquired by Pfizer) to advance a portfolio of centrally-acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). GPCRs have been proven to be the most successful class of druggable targets in the human genome and make up 50-60% of all druggable targets in the body. Longboard’s small molecule product candidates were discovered out of the same world-class GPCR research platform at Arena that represents a culmination of more than 20 years of drug development and optimization.
Our Pipeline
GPCRs are highly validated therapeutic targets.
AT LONGBOARD, WE ARE DEVELOPING THE NEXT GENERATION OF THIS PROVEN CLASS OF DRUGS
Our therapeutic candidates are designed with the selectivity and specificity of next generation therapies that may translate into favorable profiles and potentially improved safety.
Therapeutic Areas of Interest

There are multiple Developmental and Epileptic Encephalopathy (DEE) syndromes affecting infants, children and adults across the world, and there is a significant unmet need for treating and controlling multiple different seizure types across these populations. Learn more here.
Publications
American Epilepsy Society (AES) 2022 Annual Meeting
Evaluation of Prolactin as a Useful Pharmacodynamic Tool to Assess Engagement of Central 5-HT2C Receptors by LP352, a Potent and Selective 5-HT2C Agonist
Rosa Chan, Dewey McLin, Randall Kaye
Searching for Safer and More Effective Medications in the Management of Seizure Disorders: A 5-HT2C Superagonist
Randall Kaye, Graeme Semple, David Unett, Ibragim Gaidarov, Todd Anthonye
American Academy of Neurology (AAN) Annual Meeting 2022
Single Ascending Dose Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability of LP352 in Healthy Subjects
Dolly A. Parasrampuria, Ian Mills, Gale O’Connell, Archana Chaudhary, Jon Ruckle, Chad Orevillo, Phil Perera
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability Study of LP352 in Healthy Subjects
Dolly A. Parasrampuria, Ian Mills, Gale O’Connell, Archana Chaudhary, Jon Ruckle, Chad Orevillo, Phil Perera